Among the approvals is the request for use of the innovative drug in the patient Constança Bradell, who complained about the delay in approval in Portugal of the treatment for cystic fibrosis, a genetic, hereditary and rare disease.

The clinical director of the CHULN said that the innovative treatment could soon reach five more patients from that hospital centre, which includes the Santa Maria Hospital and Pulido Valente Hospital.